TAK-071

Phase 2Small molecule

Takeda

TAK-071 is one of 105 small molecule programs targeting Psychiatric Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psychiatric DisorderActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Parkinson DiseaseActive, not recruiting

Psychiatric DisorderPhase 1

Active, not recruiting

Cognitive ImpairmentPhase 1

Active, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Provigil

NNuvo Research GmbH

Phase 3

1 4

Xarelto

WWim Janssens

Phase 3

1 5

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 6

Viagra

VViatris Specialty LLC

Phase 3

1 7

Donepezil Hydrochloride

Eisai

Phase 3

3 8

Statins

Sanofi

Phase 3

1 9

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

4 10

Karx-EC

Bristol-Myers Squibb

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cognitive impairment2 trials

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Terminated· Takeda logo

Takeda·Phase 1·NCT02918266·18 enrolled

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Terminated· Takeda logo

Takeda·Phase 1·NCT02769065·179 enrolled

Parkinson disease1 trial

A Study of TAK-071 in People With Parkinson Disease

Completed· Takeda logo

Takeda·Phase 2·NCT04334317·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TAK-071. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-071 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-071. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

TAK-071

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cognitive impairment2 trials

Parkinson disease1 trial

References

Drug Info

Quick Facts

Related News